新生血管性年龄相关性黄斑变性治疗范式的演变:真实世界证据综述
本文通过PubMed文献检索,综述抗VEGF(血管内皮生长因子)药物治疗新生血管性年龄相关性黄斑变性(nAMD)的真实世界证据。综述汇总PRN、T&E和固定双月给药方案的证据,指出真实世界证据表明T&E方案在优化视觉结局的同时减轻患者、诊所和医生负担。T&E方案最有可能在临床结局与治疗负担之间取得平衡。
要点
- 真实世界证据推动nAMD抗VEGF治疗策略的改进与优化。
- 与固定剂量和PRN方案相比,T&E方案优化视觉结局并减轻治疗负担。
- 在现有方案中,T&E最可能兼顾临床结局与治疗负担。
核心结论
- 真实世界证据帮助开发并改进了nAMD的真实世界治疗策略,目标是优化视觉结局并减少临床实践中的治疗负担。
- 在各类方案中,T&E方案最有可能为nAMD患者充分平衡临床结局与治疗负担。
研究设计与样本
- 本文为综述,通过PubMed文献检索回顾大量英文研究,评估抗VEGF(阿柏西普和雷珠单抗)治疗nAMD的真实世界有效性。
主要发现
- 综述回顾并总结了PRN、T&E和固定双月给药方案用于nAMD抗VEGF治疗的证据。
- 真实世界证据显示,与固定剂量和PRN方案相比,T&E方案优化视觉结局,同时减轻患者、诊所和医生的负担。
临床怎么用
- 临床可参考真实世界证据选择抗VEGF给药方案,T&E方案可能更利于兼顾视觉结局与治疗负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The aim of this work was to evaluate the contribution of real-world evidence (RWE) in changing anti-vascular endothelial growth factor (VEGF) therapy treatment practices and improving real-world treatment strategies for neovascular age-related macular degeneration (nAMD).A PubMed literature search was performed to review the large number of English-language studies conducted to investigate the real-world effectiveness of anti-VEGF (aflibercept and ranibizumab) treatment paradigms available for nAMD.The evidence for pro re nata (PRN), treat-and-extend (T&E) and fixed bimonthly dosing regimens for anti-VEGF treatment of nAMD were reviewed and findings are summarised. RWE demonstrated that T&E regimens optimise visual outcomes while reducing burden on patients, clinics and physicians, compared with both fixed-dose and PRN regimens.RWE has helped to develop and improve real-world treatment strategies in nAMD, with the aim of optimising visual outcomes and reducing treatment burden in clinical practice. Of the various regimens, a T&E regimen is most likely to adequately balance clinical outcomes and treatment burden for patients with nAMD.
引用
- Daien V, Finger RP, Talks JS, et al. Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence. Br J Ophthalmol. 2020. PMID: 33130553. doi:10.1136/bjophthalmol-2020-317434
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。